asciminib (Scemblix)

Introduction

Indcations:

• treatment of chronic myeloid leukemia
  • Philadelphia chromosome-positive CML in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibito

Adverse effects

• upper respiratory tract infections
• musculoskeletal pain
• thrombocytopenia
• neutropenia
• anemia
• hypertriglyceridemia
• increase in serum creatine kinase & serum alanine aminotransferase

Mechanism of action

• acts as a STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor.

More general terms

• small inhibitory antineoplastic agent (ib drug)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=72165228
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=133082086
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=129010150